David F. Penson, MD, MPH, answers Cancer Therapy Advisor's questions on the most key recent developments in prostate cancer management.
Patients receiving systemic therapy for metastatic non-small cell lung cancer (mNSCLC) outside of clinical trials are hospitalized significantly more often.
Patients with stage 4 lung cancer who quit smoking showed an improvement in overall survival, even if they quit before chemotherapy.
[Clinical Medicine Insights: Oncology] Although myelosuppression is the most adverse event of this therapy, gemcitabine might induce severe pulmonary toxicities.
From Oncology Nurse Advisor
Sign Up for Free e-newsletters
Breast Cancer Awareness Month Poll
Cancer Therapy Advisor Articles
- Will Epigenetic Drugs Improve Immunotherapy Outcomes?
- Preoperative Breast MRI Associated With Longer Wait Time to Surgery
- Quitting Smoking Prior to Chemo Linked to Improved Survival Rate in Stage 4 Lung Cancer
- PD-L1 May Predict Response to TKIs, VEGFs in Metastatic Clear Cell Renal Cell Carcinoma
- Hyper-CVAD Plus Ponatinib May Be Effective for Newly Diagnosed Ph+ Acute Leukemia
- Identifying Allele Mismatch in aGVHD With Genome-Wide Surveillance
- Preop Proteinuria Predicts Overall Survival in Kidney Cancer
- Partner-assisted Skin Exams Benefit Some More Than Others
- New Staging System for Intrahepatic Cholangiocarcinoma May Benefit Potential Surgery Patients
- Volume Re-classification Portends Grade Re-classification in Gleason 6 Prostate Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|